These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 27572607)

  • 21. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
    Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
    Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
    Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
    J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
    Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAF
    Aldaghi SA; Jalal R
    Chem Res Toxicol; 2019 Apr; 32(4):645-658. PubMed ID: 30829029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
    Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
    Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.
    Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G
    J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.
    Johnson DB; Menzies AM; Zimmer L; Eroglu Z; Ye F; Zhao S; Rizos H; Sucker A; Scolyer RA; Gutzmer R; Gogas H; Kefford RF; Thompson JF; Becker JC; Berking C; Egberts F; Loquai C; Goldinger SM; Pupo GM; Hugo W; Kong X; Garraway LA; Sosman JA; Ribas A; Lo RS; Long GV; Schadendorf D
    Eur J Cancer; 2015 Dec; 51(18):2792-9. PubMed ID: 26608120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
    Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
    J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition.
    Phadke M; Remsing Rix LL; Smalley I; Bryant AT; Luo Y; Lawrence HR; Schaible BJ; Chen YA; Rix U; Smalley KSM
    Mol Oncol; 2018 Jan; 12(1):74-88. PubMed ID: 29112787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.
    Sharma R; Fedorenko I; Spence PT; Sondak VK; Smalley KS; Koomen JM
    J Proteome Res; 2016 Dec; 15(12):4476-4489. PubMed ID: 27934295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
    Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
    J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
    Gallagher SJ; Gunatilake D; Beaumont KA; Sharp DM; Tiffen JC; Heinemann A; Weninger W; Haass NK; Wilmott JS; Madore J; Ferguson PM; Rizos H; Hersey P
    Int J Cancer; 2018 May; 142(9):1926-1937. PubMed ID: 29210065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
    Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
    Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
    J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
    Walter L; Heinzerling L
    Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.
    Dugo M; Nicolini G; Tragni G; Bersani I; Tomassetti A; Colonna V; Del Vecchio M; De Braud F; Canevari S; Anichini A; Sensi M
    Oncotarget; 2015 Mar; 6(7):5118-33. PubMed ID: 25742786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells.
    Ross KC; Andrews AJ; Marion CD; Yen TJ; Bhattacharjee V
    Mol Cancer Ther; 2017 Aug; 16(8):1596-1609. PubMed ID: 28500236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
    Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H
    Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
    Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
    Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.